Company: STAA
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284603
Chunk: 15

Company: STAAR SURGICAL CO
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 15
---
 Agreement—Termination Fees.” Pursuant to the Amendment, the termination fee payable by STAAR to Alcon has been reduced to $0 in certain circumstances, including if STAAR terminates the Merger Agreement to accept a Superior Offer from a Qualified Bidder, as described in the “The Merger Agreement—Amendment.”

The following text is added at the end of the third bullet under each section titled “Effect on STAAR if the Merger Is Not Completed” on pages 11 and 34 of the proxy statement:

Pursuant to the Amendment, the termination fee payable by STAAR to Alcon has been reduced to $0 in certain circumstances, including if STAAR terminates the Merger Agreement to accept a Superior Offer from a Qualified Bidder, as described in the “The Merger Agreement—Amendment.”

Set forth below are further supplemental disclosures with respect to the “Background of the Merger” section of the proxy statement to reflect relevant developments that have occurred since the filing of the supplement to the proxy statement dated October 30, 2025 (the “Prior Supplement”).

Supplemental Disclosures to the Proxy Statement in Connection with the Background of the Merger

The proxy statement describes the background of the Merger up to and including October 27, 2025, and is hereby amended by inserting the following text below the final paragraph on page 16 of the Prior Supplement:

Between October 27, 2025, and October 28, 2025, Mr. Farrell and Mr. Endicott discussed further the potential terms of an amendment to the Merger Agreement. During such discussions, Alcon raised the possibility of waiving the non-solicitationrestrictions under the Merger Agreement to facilitate a go-shopperiod.

On October 28, 2025, the Board met with members of STAAR’s management and representatives of Citi and Wachtell Lipton to continue its discussion of a potential amendment to the Merger Agreement and the potential advantages and disadvantages of such an amendment or a waiver by Alcon of the non-solicitationrestrictions under the Merger Agreement. Following discussion, the Board reaffirmed its prior determination that it would not, at that time, accept Alcon’s proposal to amend the terms of the Merger Agreement without a concurrent commitment to increase price.

On November 2 and 3, 2025, Mr. Farrell continued to engage in discussions with Mr. Endicott regarding the terms of a potential amendment to the Merger Agreement.

On